177lu-psma-618
novartis
['lu-177', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
we need better strategies in the post lu-177 psma setting. efficacy of systemic therapy ~12% psa response ( 50%) . psa-pfs 3.5 months, median os 6.6 months. #gu23 : 
Working together to improve patient outcomes with personalised medicine: PET/CT, theranostics. Nuclear Medicine Physician ☢️ Prof 🇦🇺